2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
Ioannidis J, Rosenberg P, Goedert J, Ashton L, Benfield T, Buchbinder S, Coutinho R, Eugen-Olsen J, Gallart T, Katzenstein T, Kostrikis L, Kuipers H, Louie L, Mallal S, Margolick J, Martinez O, Meyer L, Michael N, Operskalski E, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Stewart G, Theodorou I, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury J, O'Brien T. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Annals Of Internal Medicine 2001, 135: 782-95. PMID: 11694103, DOI: 10.7326/0003-4819-135-9-200111060-00008.Peer-Reviewed Original ResearchConceptsHIV-1 infectionCCR2-64I alleleHIV-1 RNA levelsHIV-1 disease progressionDevelopment of AIDSIndividual patient dataCCR5-Delta32Decreased riskDisease progressionProtective effectLower HIV-1 RNA levelsRNA levelsProspective cohort studyCase-control studyClear protective effectStrong protective effectChemokine receptor genesRandom-effects modelCCR2-64ICohort studyStudy entryCertain chemokinesAIDSInfectionProgression
1995
Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A
Vlahov D, Khabbaz R, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 9: 89-96. PMID: 7712239, DOI: 10.1097/00042560-199505010-00013.Peer-Reviewed Original ResearchConceptsRisk factorsDrug usersEnzyme immunoassayWestern blotHuman T-lymphotropic virusNeedle-sharing practicesRisk factor analysisT-lymphotropic virusMedian lag timeCase-control designALIVE studyRecent serumSeronegative IDUsStudy entryBaseline historyIncidence rateSeroconversionPositive casesSex partnersIDUsHTLVCalendar timeMonthsIncidenceBaseline
1994
Field effectiveness of needle disinfection among injecting drug users.
Vlahov D, Astemborski J, Solomon L, Nelson K. Field effectiveness of needle disinfection among injecting drug users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1994, 7: 760-6. PMID: 8207660.Peer-Reviewed Original ResearchConceptsHIV seroconversionOdds ratioDrug usersNeedle disinfectionPutative protective effectCase-control studyCorresponding odds ratiosSterile injection equipmentDisinfectant useInjection equipmentLimited statistical powerStudy entryHIV seroconvertersResidual confoundingPossible confoundersCocaine injectionProtective effectSeroconversionDrug useUse of disinfectantsBlack heterosexualsPractice variablesField effectivenessSeroconvertersSeronegativesDirect Comparison of the Relationship Between Clinical Outcome and Change in CD4+ Lymphocytes in Human Immunodeficiency Virus—Positive Homosexual Men and Injecting Drug Users
Margolick J, Muñoz A, Vlahov D, Astemborski J, Solomon L, He X, Nelson K, Saah A. Direct Comparison of the Relationship Between Clinical Outcome and Change in CD4+ Lymphocytes in Human Immunodeficiency Virus—Positive Homosexual Men and Injecting Drug Users. JAMA Internal Medicine 1994, 154: 869-875. PMID: 7908795, DOI: 10.1001/archinte.1994.00420080065006.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus-positive homosexual menLymphocyte countHomosexual menImmunodeficiency syndromeDrug usersRate of declineStudy entryClinical outcomesHuman immunodeficiency virus (HIV) infectionDevelopment of thrushMore frequent developmentImmunodeficiency virus infectionT cell subsetsInjecting Drug UsersProgression of diseaseRisk group membershipLower absolute numbersLymphocyte numbersClinical progressionClinical symptomsInitial levelDisease progressionVirus infectionStudy groupCD4
1993
Differences in Risk Factors for Human Immunodeficiency Virus Type 1 Seroconversion among Male and Female Intravenous Drug Users
Solomon L, Astemborski J, Warren D, Muñoz A, Cohn S, Vlahov D, Nelson K. Differences in Risk Factors for Human Immunodeficiency Virus Type 1 Seroconversion among Male and Female Intravenous Drug Users. American Journal Of Epidemiology 1993, 137: 892-898. PMID: 8484380, DOI: 10.1093/oxfordjournals.aje.a116750.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman immunodeficiency virus type 1 (HIV-1) seroconversionDrug usersSeronegative controlsRisk factorsFemale intravenous drug usersMale intravenous drug usersSex-specific risk factorsCurrent intravenous drug useHIV-seronegative controlsIntravenous drug useRisk of seroconversionRisk factor dataCase-control studyAge 18 yearsConditional logistic regression techniquesTime of interviewMore sex partnersSeroconversion statusSeroconversion visitHIV seroconversionHIV infectionStudy entrySexual transmissionSeroconversion
1991
HIV SEROCONVERSION AND DISINFECTION OF INJECTION EQUIPMENT AMONG INTRAVENOUS DRUG USERS, BALTIMORE, MARYLAND
Vlahov D, Muntoz A, Celentano D, Cohn S, Anthony J, Chiicoat H, Nelson K. HIV SEROCONVERSION AND DISINFECTION OF INJECTION EQUIPMENT AMONG INTRAVENOUS DRUG USERS, BALTIMORE, MARYLAND. Epidemiology 1991, 2: 444-446. PMID: 1790197, DOI: 10.1097/00001648-199111000-00010.Peer-Reviewed Original ResearchConceptsIntravenous drug usersDrug usersHIV seroconversionProtective effectUse of disinfectantsPutative protective effectCase-control studyCorresponding odds ratiosOdds of seroconversionDisinfectant useLimited protective effectUse of cocaineStudy entryHIV seroconvertersOdds ratioSeroconversionInjection equipmentOddsSeroconvertersSeronegativesDisinfectants